Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stewart Reid

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Infectious Diseases|March 11, 2010
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trialJonathan Fuchs, Connie Celum, Jing Wang, et al.
Plos One|October 27, 2010
Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemicDon Bandaranayake, Q Sue Huang, Ange Bissielo, et al.
Plos One|July 21, 2010
Strengthening health systems at facility-level: feasibility of integrating antiretroviral therapy into primary health care services in lusaka, zambiaStephanie M Topp, Julien M Chipukuma, Mark Giganti, et al.
Tobacco Prevention & Cessation|May 16, 2020
Building capacity to implement tobacco-free policies in college and university settings with underserved populationsJessica M Rath, Lindsay Pitzer, Brittany Carnegie, et al.
The Pediatric Infectious Disease Journal|April 7, 2007
New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 monthsSharon Wong, Diana Lennon, Catherine Jackson, et al.
The Pediatric Infectious Disease Journal|April 23, 2009
Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccineSharon H Wong, Diana R Lennon, Catherine M Jackson, et al.
Clinical and Vaccine Immunology : CVI|September 28, 2007
Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteensJamie Hosking, Kumanan Rasanathan, Florina Chan Mow, et al.
Human Vaccines|July 31, 2007
Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006Anne McNicholas, Yvonne Galloway, Paul Stehr-Green, et al.
International Journal of Epidemiology|February 19, 2009
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, ZambiaBenjamin H Chi, Ronald A Cantrell, Isaac Zulu, et al.
Lancet (London, England)|June 24, 2008
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trialConnie Celum, Anna Wald, James Hughes, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Infectious Diseases|March 11, 2010
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trialJonathan Fuchs, Connie Celum, Jing Wang, et al.
Plos One|October 27, 2010
Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemicDon Bandaranayake, Q Sue Huang, Ange Bissielo, et al.
Plos One|July 21, 2010
Strengthening health systems at facility-level: feasibility of integrating antiretroviral therapy into primary health care services in lusaka, zambiaStephanie M Topp, Julien M Chipukuma, Mark Giganti, et al.
Tobacco Prevention & Cessation|May 16, 2020
Building capacity to implement tobacco-free policies in college and university settings with underserved populationsJessica M Rath, Lindsay Pitzer, Brittany Carnegie, et al.
The Pediatric Infectious Disease Journal|April 7, 2007
New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 monthsSharon Wong, Diana Lennon, Catherine Jackson, et al.
The Pediatric Infectious Disease Journal|April 23, 2009
Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccineSharon H Wong, Diana R Lennon, Catherine M Jackson, et al.
Clinical and Vaccine Immunology : CVI|September 28, 2007
Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteensJamie Hosking, Kumanan Rasanathan, Florina Chan Mow, et al.
Human Vaccines|July 31, 2007
Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006Anne McNicholas, Yvonne Galloway, Paul Stehr-Green, et al.
International Journal of Epidemiology|February 19, 2009
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, ZambiaBenjamin H Chi, Ronald A Cantrell, Isaac Zulu, et al.
Lancet (London, England)|June 24, 2008
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trialConnie Celum, Anna Wald, James Hughes, et al.
Pageof 4